Loading...
Loading...
HALO| Name | Value |
|---|---|
| Revenues | 216.0M |
| Cost of Revenue | 54.8M |
| Gross Profit | 161.2M |
| Operating Expense | 72.9M |
| Operating I/L | 88.3M |
| Other Income/Expense | 13.5M |
| Interest Income | 3.5M |
| Pretax | 101.8M |
| Income Tax Expense | 19.9M |
| Net Income/Loss | 81.8M |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company, specializing in the ENHANZE drug delivery technology. Their flagship product, Hylenex recombinant, utilizes rHuPH20 to facilitate subcutaneous fluid administration and enhance the dispersion and absorption of other injected drugs. The company also develops various treatments for non-Hodgkin lymphoma, chronic lymphocytic leukemia, multiple sclerosis, and other conditions. They generate revenue through collaborations with pharmaceutical companies, including F. Hoffmann-La Roche, Ltd., Pfizer Inc., and Bristol-Myers Squibb Company, for the development of small and large molecule targets for the treatment and prevention of HIV, as well as through the sale of their own products.
